Clinical Aspects of Interventional Treatment of a Patient With Atrial Fibrillation Combined With Resistant Arterial Hypertension by the Method of Radiofrequency Ablation in Renal Arteries and Left Atrium

резистентная артериальная гипертензия , фибрилляция предсердий , абляция в почечных артериях , абляция фибрилляции предсердий , resistant arterial hypertension, atrial fibrillation , ablation in the renal arteries , ablation of atrial fibrillation

1. Miyasaka Y., Barnes M.E., Gersh B.J. et al. Secular trends in incidence of atrial fibrillations in Olmsted Country, Minnecota, 19802000, and implications on the projections on future prevalence. Circulation 2006; 114: 119-125.

2. Stewart S., Hart C., Hole D., McMurray J. A population-based study of the long-term risk associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113 (5): 359-364.

3. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1-e88.

4. Goette A., Schon N., Kirchhof P. et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5: 43-51.

5. Yusuf S., Healey J.S., Pogue J. et al. Active I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928-938.

6. Rimoldi S.F., Franz H., Messerli F.H. et al. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015; 36 (40): 2686-2695.

7. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403-1419.

8. Sievert H., Schofer J., Ormiston J.A. et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention 2015; 10: 1213-1220.

9. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.

10. Symplicity HTN-2 Investigators, Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.

11. Bhatt D.L., Kandzari D.E., O'Neill W.W. et al.; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.

12. Pathak A., Ewen S., Fajadet J. et al. From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? EuroIntervention 2014; 10: 21-23.

13. Luscher T.F., Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014; 35: 1706-1711.

14. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281-1357.

15. Hering D., Mahfoud F., Walton A.S. et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23 (7): 1250-1257.